非小细胞肺癌常用酪氨酸激酶抑制剂的治疗药物监测研究进展
Research progress of therapeutic drug monitoring of tyrosine kinase inhibitors commonly used in non-small cell lung cancer
周国进 1伍晶晶 2许静 3陈杰2
作者信息
- 1. 中山大学附属第一医院药学部,广州 510080;中山大学药学院,广州 510006
- 2. 中山大学附属第一医院药学部,广州 510080
- 3. 南方医科大学皮肤病医院药剂科,广州 510091
- 折叠
摘要
酪氨酸激酶抑制剂显著改善了晚期非小细胞肺癌患者的预后,然而临床实践发现其疗效及药动学存在较大个体差异,故相继有研究者采用治疗药物监测指导个体化用药并取得较好效果.但部分酪氨酸激酶抑制剂尚缺乏相应的目标浓度或治疗窗,且其暴露-效应关系仍不明确.因此,本文将对晚期非小细胞肺癌常用一线口服靶向药物吉非替尼、厄洛替尼、埃克替尼、阿法替尼、达可替尼、奥希替尼、阿来替尼、克唑替尼和塞瑞替尼等药物的治疗药物监测研究现状做一综述,以期为临床实践提供参考.
Abstract
Tyrosine kinase inhibitors have dramatically improved the prognosis of patients with advanced non-small cell lung cancer.In clinical settings,however,it is observed that the treatment response and pharmacokinetics show the characteristics of substantial variability among individuals.In such case,therapeutic drug monitoring is applied to guiding personalized medicine by researchers in succession and has remarkable results.Yet some of the tyrosine kinase inhibitors are still lack of corresponding target concentration or therapeutic window,and the exposure-response relationship remains unclear.Therefore,the aim of this review is to elucidate the current research progress of therapeutic drug monitoring for the first-line oral targeted drugs commonly used in advanced non-small cell lung cancer,such as gefitinib,erlotinib,icotinib,afatinib,dacomitinib,osimertinib,alectinib,crizotinib and ceritinib,in order to provide reference for clinical practice.
关键词
肺癌/酪氨酸激酶抑制剂/治疗药物监测/药动学/暴露-效应关系Key words
lung cancer/tyrosine kinase inhibitor/therapeutic drug monitoring/pharmacokinetic/exposure-response relationship引用本文复制引用
基金项目
广东省基础与应用基础研究基金企业联合基金项目(2021A1515220165)
广东省药理学会基于电子病历建立药品不良事件触发器主动监测应用研究基金项目(GYLY2021008)
广东省科技创新战略专项资金项目(2018A030313138)
广东省临床用药研究基金项目(2022JZ33)
出版年
2024
NETL
NSTL
维普
万方数据